DTC Pre-Review Guidance Could Make Promotional Campaigns More Costly
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA’s assistant general counsel says that FDA’s draft might increase expenses because of the need to submit final ads in advance and the potential to be asked for extensive revisions.